Publication:
NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus

Simple item page
dc.contributor.authorCarrasco, Javiera
dc.contributor.authorSandoval, Felipe
dc.contributor.authorSchuh, Christina
dc.contributor.authorLagos, Carlos
dc.contributor.authorMorales, Javier
dc.contributor.authorArriagada, Francisco
dc.contributor.authorOrtiz, Andrea
dc.date.accessioned2026-08-20T17:10:25Z
dc.date.available2026-08-20T17:10:25Z
dc.date.issued2025
dc.description.abstractBackground/Objectives: Rifampicin is a typical antibiotic used for the treatment of Staphylococcus aureus (S. aureus) infections; however, its clinical utility is limited by poor aqueous solubility, chemical instability, and increasing bacterial resistance. Nanostructured lipid carriers (NLCs) offer a promising strategy to improve drug solubility, stability, and antimicrobial performance. Methods: In this study, rifampicin-loaded NLC (NLC-RIF) was developed using a hot homogenization with a low energy method and characterized in terms of particle size, polydispersity index, zeta potential, encapsulation efficiency, colloidal stability, and drug loading. Results: In vitro release studies under sink conditions demonstrated a biphasic release pattern, best described by the Korsmeyer-Peppas model, suggesting a combination of diffusion and matrix erosion mechanisms. Antimicrobial activity against S. aureus revealed a substantial increase in potency for NLC-RIF, with an IC50 of 0.46 ng/mL, approximately threefold lower than that of free rifampicin. Cytotoxicity assays in HepG2 cells confirmed over 90% cell viability across all tested concentrations. Conclusions: These findings highlight the potential of NLC-RIF as a biocompatible and effective nanocarrier system for enhancing rifampicin delivery and antibacterial activity.
dc.description.versionVersión Publicada
dc.identifier.citationCarrasco-Rojas J, Sandoval FI, Schuh CMAP, Lagos CF, Morales JO, Arriagada F, Ortiz AC. NLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus. Pharmaceutics. 2025 Jun 19;17(6):799. doi: 10.3390/pharmaceutics17060799.
dc.identifier.doihttps://doi.org/10.3390/pharmaceutics17060799
dc.identifier.urihttps://hdl.handle.net/11447/11027
dc.language.isoen
dc.subjectHepG2 cell
dc.subjectStaphylococcus aureus
dc.subjectAntibiotic
dc.subjectDrug release
dc.subjectNanostructured lipid carrier
dc.titleNLC-Based Rifampicin Delivery System: Development and Characterization for Improved Drug Performance Against Staphylococcus aureus
dc.typeArticle
dcterms.accessRightsAcceso Abierto
dcterms.sourcePharmaceutics
dspace.entity.typePublication

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
NLC-Based Rifampicin Delivery System Development and.pdf
Size:
1.23 MB
Format:
Adobe Portable Document Format
Description:
Texto Completo
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
347 B
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Artículos Medicina y Ciencias de la Salud

Implementado por OpenGeek Services